Abstract

Viral vectors facilitate the delivery of genetic material to living cells for the potential treatment of multiple genetic diseases. With recent regulatory approvals, the rapid growth in demand for viral vector-based products highlights the need for proven, scalable manufacturing solutions that can fully meet this demand and ultimately increase the availability of viral vector-based treatments. Pall’s AllegroTM STR stirred-tank bioreactor addresses the need for scalability, as it can be scaled up to 2000 L to enable the manufacture of viral vectors. In this article, we discuss the key attributes of the Allegro STR bioreactor such as the design, scalability, agitation and sparging which make it ideal for viral vector manufacture at a larger scale. Also, we show process scalability under controlled key parameters from Allegro STR 50 L to 500 L based on cell growth, metabolic profile, and viral vector production.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call